Cyclerion Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CYCN Nasdaq 8731 https://www.cyclerion.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cyclerion Therapeutics Inc

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results - Mar 22nd, 2023 8:40 pm
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company - Nov 22nd, 2022 12:00 pm
Cyclerion Therapeutics Third Quarter 2022 Earnings: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021) - Nov 9th, 2022 11:34 am
Cyclerion Therapeutics lays off nearly half of workforce - Oct 7th, 2022 6:31 pm
Cyclerion Shares Fall After Reprioritized Pipeline, Workforce Reduction - Oct 6th, 2022 4:46 pm
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy - Oct 6th, 2022 12:00 pm
Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates - Aug 9th, 2022 9:35 pm
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results - Aug 9th, 2022 8:00 pm
Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth? - Aug 8th, 2022 1:22 pm
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS) - Jul 28th, 2022 11:00 am
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors - Jul 26th, 2022 11:00 am
Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation - Jun 28th, 2022 1:00 pm
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation - Jun 22nd, 2022 12:30 pm
Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies - Jun 17th, 2022 3:20 pm
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease - Jun 17th, 2022 12:00 pm
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium - Jun 10th, 2022 11:00 am
Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium - Jun 6th, 2022 11:00 am
As Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) drops to US$26m market cap, insiders might rethink their US$2.7m stock purchase earlier this year - May 11th, 2022 1:30 pm
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results - May 4th, 2022 8:01 pm